21基因复发评分对年轻女性淋巴结阴性及阳性ER阳性/HER2阴性乳腺癌的预后影响
该研究基于年轻女性乳腺癌前瞻性队列(≤40岁,N=1302),分析577例I-III期ER+/HER2-患者,其中189例临床检测RS,320例用库存标本补测。中位随访6.0年,结果显示RS在N0和N1患者中均具有预后价值,N0且RS≥26或N1且RS≥11者早期远处复发风险较高。
要点
- 年轻女性(≤40岁)ER+/HER2-乳腺癌中,21基因RS可区分N0和N1患者的远处复发风险。
- N0且RS 0-25者6年DRFS良好,N0且RS≥26者早期远处复发风险显著增加。
- N1且RS<11者6年DRFS良好,N1且RS≥11者早期远处复发风险较高。
核心结论
- 21基因复发评分在年轻女性淋巴结阴性和有限淋巴结阳性乳腺癌中具有预后价值,是风险分层的有效工具。
研究设计与样本
- Young Women's Breast Cancer Study为前瞻性队列,纳入2006至2016年确诊的≤40岁乳腺癌患者N=1302。
- 分析纳入I-III期ER+/HER2-乳腺癌患者N=577,其中189例(33%)临床检测RS,320例(56%)库存标本补测。
主要发现
- 中位随访6.0年,诊断时中位年龄37.2岁;509例中300例(59%)为N0,其中195例(65%)RS为11-25,195例中86例(44%)接受化疗。
- N0患者6年DRFS:RS<11为94.4%,RS 11-25为96.9%,RS≥26为85.1%。
- N1患者6年DRFS:RS<11为92.3%,RS 11-25为85.2%,RS≥26为71.3%。
关键数值与推荐
- RS风险分组采用TAILORx和传统RS风险组标准。
- N0且RS 0-25(少数接受化疗)及N1且RS<11者6年DRFS良好;N0且RS≥26或N1且RS≥11者早期远处复发风险显著。
临床怎么用
- 对≤40岁ER+/HER2-乳腺癌患者,RS可用于辅助风险分层,尤其N0且RS≥26或N1且RS≥11者需警惕早期远处复发。
局限性
- 部分患者RS为库存标本补测而非临床检测;年轻女性在既往基因表达谱研究中占比较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer and is used to inform recommendations for chemotherapy. Women ≤ 40 years of age represent a minority of patients studied using gene expression profiles. METHODS: The Young Women's Breast Cancer Study is a prospective cohort of women diagnosed with breast cancer at age ≤ 40 years and enrolled patients between 2006 and 2016 (N = 1,302). We identified patients with stage I-III ER+/HER2- breast cancer. The RS assay was performed on banked specimens for patients who had not been tested clinically. Distant recurrence-free survival (DRFS) was assessed by TAILORx and traditional RS risk groups among patients with axillary node-negative (N0) and limited node-positive (N1) breast cancer. RESULTS: Among eligible women (N = 577), 189 (33%) had undergone RS testing, and 320 (56%) had banked specimens sufficient for testing. Median follow-up was 6.0 years. Median age at diagnosis was 37.2 years; 300 of 509 patients (59%) had N0 breast cancer, of whom 195 (65%) had an RS of 11-25 and fewer than half (86 of 195; 44%) received chemotherapy. Six-year DRFS rates were 94.4% and 92.3% (RS < 11), 96.9% and 85.2% (RS 11-25), and 85.1% and 71.3% (RS ≥ 26) among women with N0 and N1 disease, respectively. CONCLUSION: The RS assay is prognostic among young women with node-negative and limited node-positive breast cancer, representing a valuable tool for risk stratification. Disease outcomes with a median follow-up of 6 years among young women with N0 disease and an RS of 0-25, a minority of whom received chemotherapy, and node-positive disease with an RS < 11 were very good, whereas those with N0 disease and an RS ≥ 26 or N1 disease with an RS ≥ 11 experienced substantial risk of early distant recurrence.
引用
- Poorvu PD, Gelber SI, Rosenberg SM, et al. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. J Clin Oncol. 2019. PMID: 31809240. doi:10.1200/JCO.19.01959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。